Background. Autosomal recessive polycystic kidney disease (ARPKD) [MIM 263200] belongs to a group of congenital hepatorenal fibrocystic syndromes and is caused by mutations in the PKHD1 gene encoding the multidomain protein fibrocystin/polyductin (FPC). The serine-threonine kinase mammalian target of rapamycin (mTOR) is one of the most important gate-keepers integrating numerous signals related to cell proliferation and growth. Whereas the direct activation of mTOR has been shown recently in autosomal-dominant PKD, no data are available on the role of mTOR signalling in proliferation and progression of ARPKD. Methods. Formalin-fixed and paraffin-embedded kidney specimens obtained during nephrectomy from children with ARPKD (n = 12) were used for immunohistochemical investigation of FPC expression (monoclonal antibody (mAb) 18, mAb 5a), proliferative activity (Ki-67) and activation of the mTOR pathway. Kidney specimens from children (n = 4) who died from causes not associated with kidney disease served as controls. For the detection of AKT, mTOR and S6K antibodies specifically recognizing the activated (phosphorylated) isoforms of these proteins were used. In all patients mutation analysis of the PKHD1 gene was performed. Results. In 10 out of 12 patients, we could confirm the diagnosis by the identification of PKHD1 mutations. The tubular cyst epithelium of all kidney specimens stained strongly positive with the FPC-specific monoclonal antibody (mAb) 18 but only very faint signals were obtained with mAb 5a. In contrast, healthy kidneys showed rather weak signals with both FPC-specific mAbs, indicating dysregulated expression of FPC in our patients. Phosphorylated AKT as well as activated mTOR and its down-stream effector S6K were strongly expressed in cystic epithelia of all kidney specimens but not in control tissues. No association between the activation of this pathway and the proliferative activity (Ki-67 expression) was observed. Conclusions. Our results point to a central role of AKT/mTOR signalling in ARPKD and justify further investigations to evaluate the therapeutic potential of mTOR inhibitors in ARPKD patients.
Introduction
Autosomal recessive polycystic kidney disease (ARPKD) [MIM 263200] belongs to a group of congenital hepatorenal fibrocystic syndromes and is caused by mutations in the PKHD1 gene on chromosome 6p12. ARPKD occurs with an estimated frequency of 1 in 20 000 live births, has a calculated carrier frequency of 1/70 in non-isolated populations and is an important cause of renal-and liver-related morbidity and mortality in neonates and infants [1] [2] [3] [4] . Despite a considerably broad spectrum of symptoms, fusiform dilation of the renal collecting ducts and distal tubuli as well as dysgenesis of the hepatic portal triad (ductal plate malformation) are invariable histological manifestations of the disease. The PKHD1 gene encodes a multidomain integral membrane protein (fibrocystin/polyductin; FPC) of 4074 amino acids (aa) [2, 3, 5, 6] . FPC consists of a large and extensively gylcosylated N-terminal extracellular domain, followed by a short transmembranous domain and a cytoplasmatic tail, which harbours four potential phosphorylation sites. These features, together with data obtained from in vitro experiments, indicate that FPC is likely to participate in signal transduction processes [7, 8] . Evidence 1820 D. C. Fischer et al. was obtained that FPC and the autosomal-dominant polycystic kidney disease (ADPKD) proteins polycystin-1 and -2 (PC-1, PC-2) do not only co-localize to the primary cilium, but also show functionally relevant interaction [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . This might explain why ARPKD and ADPKD apart from all clinical and genetic differences are rather similar and has lead to the 'ciliary hypothesis' for PKD [19] [20] [21] . In general, cystic epithelia have lost polarization, show an increased expression of EGF-R family members together with an enhanced susceptibility for growth factors and an impaired intracellular calcium homeostasis. All together, these features result in dysregulated proliferation [3, 12, 22, 23] .
The serine/threonine kinase mammalian target of rapamycin (mTOR) is an evolutionary conserved signalling molecule, integrating a broad spectrum of signals and environmental cues, including oxidative stress, availability of nutrients and energy. Under physiological conditions, growth and proliferation requires both an appropriate stimulus and a favourable environment [24, 25] . In contrast, malignant (cancer) and benign human proliferative disorders including ADPKD are frequently accompanied by aberrant activation of the mTOR signalling pathway [13, [26] [27] [28] [29] . Furthermore, rapamycin as an inhibitor of mTOR-signalling was shown to attenuate proliferation-related progression of these diseases [13, [26] [27] [28] [29] [30] [31] [32] .
AKT is an important upstream regulator of mTOR and can be envisaged as a second messenger, generated through activation of PI3K by numerous cell surface receptors including receptor thyrosine kinases (RTK) [32] [33] [34] .
Here we present evidence that AKT/mTOR signalling is activated in renal tissue of children with clinically and genetically proven ARPKD. Thus, for these patients inhibition of mTOR might be an option to attenuate growth of cystic epithelium regardless of the precise (and possibly private) triggering event upstream of mTOR.
Materials and methods

Patients
The study received appropriate Ethics committee approval from the Institutional review board in accordance with the Declaration of Helsinki. Formalin-fixed, paraffin-embedded kidney specimens originating from children with clinically proven ARPKD were provided by pathology departments. The diagnosis of ARPKD was based on typical clinical signs and/or PKHD1 mutation analysis, respectively [2, 4, 35] . In all children, hemi-or total nephrectomy was performed prior to the initiation of peritoneal dialysis or renal transplantation and the material investigated is related to the first surgery. From two patients (HRO2, MS5) undergoing bilateral nephrectomy at an interval of 1 (MS5) or 2 years (HRO2) material from both kidneys was provided for analysis. Data representing ARPKDrelated morbidities, i.e. growth retardation (defined as height < −2 SD for age), systemic hypertension, portal hypertension, sonographic evidence for the directional reversal of the portal vein flow, hepato/-splenomegaly, hepatic fibrosis (patchy or diffusely increased echogenicity on ultrasound or portal tract fibrosis on liver biopsy), Caroli syndrome and cholangiodysplasia were recorded at the time of (first) nephrectomy, as this corresponds to the time of sampling (Tables 1 and 2 ). None of the data related to these patients have been published previously. Control kidneys (n = 4) were derived from children who died at a mean age of 3.5 years (20 months to 8 years) from causes not associated with kidney disease.
Reagents and supplies
Details of the specific antibodies used to detect FPC, Ki-67, phosphorylated AKT, phosphorylated mTOR and phosphorylated S6K are given in Table 3 . Biotin-conjugated secondary antibodies, enzyme-conjugated avidin-biotin complex (ABC) (Vectastain Elite kit, Burlingame, CA, USA) and VectorRed were from Vector Laboratories (Vector Laboratories, Burlingame, CA, USA). 3,3 -Diaminobenzidine (DAB; tablets of 10 mg) was purchased from Sigma (Taufkirchen, Germany). Purified IgGs from naive rabbits and mice were obtained from Santa Cruz Biotechnology (Heidelberg, Germany). All remaining chemicals were at least of analytical grade. For semiquantitative evaluation, slides were viewed with a Leica DMI 4000 microscope (Leica, Wetzlar, Germany) and a digital camera (DFC 320 R2; Leica) was used for documentation. Images from haematoxylin-eosin stained sections were taken at low magnification (macro settings) with a digital camera (Olympus SP-550 UZ).
Mutation analysis
Mutation screening was done on genomic DNA of the patients for the longest open reading frame transcript encoding the full-length FPC protein (4074 aa, GenBank NM_138694) by denaturing high performance liquid chromatography (DHPLC) on a Wave Fragment Analysis System (Transgenomic) as previously described in detail [36] .
Immunohistochemistry
Immunohistochemical analysis of tissue samples (5 µm sections mounted on Superfrost R slides) was performed according to the standard techniques [37] . Briefly, sections were deparaffvvinized in xylene and hydrated through a series of graded alcohols prior to blocking endogenous peroxidase (POD). For antigen retrieval, the slides were boiled in a 0.01 M citrate buffer (pH 6.0) using a microwave (3 × 8 Min, 450 W). Unspecific binding sites were saturated (10% horse serum in PBS; 20 min at room temperature) prior to incubation with the specific antibody (for details see Table 3 ). Subsequently, the slides were treated with a biotin-labelled secondary antibody in combination with either peroxidase or alkaline phosphatase (AP)-conjugated avidin-biotin complexes (Vectastain Elite ABC kit, Vector Laboratories) and the appropriate substrate (DAB and VectorRed, respectively). Counterstaining was carried out with haematoxylin. Slides derived from renal cell carcinoma were used as positive controls for activation of AKT/mTOR signalling cascade. For negative controls, the specific antibody was replaced by an unrelated antibody of the same subclass (isotype control) and/or blocking peptides were added during incubation with the specific antibody. For semiquantitative evaluation, four regions of interest (ROI) were selected at low magnification and four to five high-power fields per ROI were investigated with respect to the frequency and intensity of staining of cystic epithelia. Staining intensity was classified as 'absent (−), weak (+), moderate (++) or strong (+++). With the exception of Ki-67, in all samples a widespread staining of the cystic epithelia was observed. Therefore, the score is based almost exclusively on the staining intensity [37] .
Results
Clinical findings
In one patient, prenatal ultrasound revealed symmetrically enlarged echogenic kidneys and oligohydramnios. In four other patients, prenatal ultrasonographic examinations were at least suspicious for reduced renal function and diagnosis was confirmed in the first week of life. In the remaining seven children, pregnancy and birth were uneventful and the diagnosis was made postnatally (Tables 1 and 2 ). At the time of diagnosis, all patients presented with typical findings on renal ultrasound, i.e. bilaterally enlarged (>2 SD) echogenic kidneys, poor corticomedullary differentiation, pepper-salt pattern in infants and multiple small medullary cysts in older children. All of our patients are likely to represent the first affected individual within their family as all parents had a negative family history of disease and normal findings on renal ultrasound. Median age at the start of dialysis (n = 10) was 2.9 years (range: 2 days-6 years). In two patients, pre-emptive transplantation (living donor) was performed. Median age at nephrectomy was 2.9 years (range: 11 days-15 years). Seven out of twelve patients were growth retarded (i.e. < −2.0 SD) at the time of surgery. The median height SD score was −2.2 SD (range −3.83 up to 0.0 SD). With the exception of patient HH10, who had already undergone hemi-nephrectomy 11 days after birth, all patients presented with hepatosplenomegaly and only in two patients (H8, HH10) signs of hepatic fibrosis were absent at the time of surgery. In three out of 12 patients, hepatic fibrosis was confirmed histologically and these patients subsequently underwent either combined (H4 and H13) or sequential (H7) kidney-and liver transplantation. All patients required multiple antihypertensive drugs. 
PKHD1 mutation analysis
In all but two patients (H7 and H11), the clinical diagnosis of ARPKD was confirmed genetically (Table 4) . Patients H7 and H11 only harboured probable apathogenic changes that were also found among controls. In patients H12 and H13, novel and un-described mutations of the PKHD1 gene were detected that were absent among 400 tested normal chromosomes and which affect evolutionarily conserved residues. In line with previously established genotype-phenotype data regarding the mutational type, none of our patients carries a truncating or frame shift mutation [36, 38, 39] .
Immunohistochemical analysis
At first glance, all specimens impressed with their spiderweb like morphology (Figure 1 ). On microscopic examination, the typical features of ARPKD, i.e. radially orientated, dilated collecting ducts, multiple dilated cystic tubules and large cysts with variable numbers of interspersed glomeruli were clearly visible (data not shown).
Expression of fibrocystin/polyductin
Used for the detection of FPC were mAb 18, recognizing an epitope within the N-terminal domain and mAb 5a, directed against the C-terminal part of the protein. Whereas with mAb 18 intense cytosolic and membranous staining was readily detectable in almost all tubular cysts, only very faint and diffuse signals were obtained with mAb 5 (Figure 2 and Table 4 ). In contrast, with both antibodies rather weak stainings with respect to intensity and localization were observed in healthy kidneys from deceased children (Figure 2) .
Expression of Ki-67
The Ki-67 specific mAb MIB-1 [40] was employed to estimate proliferative activity in ARPKD kidneys and healthy controls (Table 4 and Figure 3A) . In only two of the available ARPKD samples, a rather homogenous distribution of Ki-67 positive cells was seen, in seven more samples occasionally positive cells were detected within the cystic The pan-specific polyclonal antibody recognizes Thr-308 phosphorylated AKT (PKB) as well as the correspondingly phosphorylated isoforms of other members of the AKT-family [58] . The selected antibody recognizes mTOR only when phosphorylated at Ser2448, which occurs via the PI3kinase/AKT signalling pathway [59] . Since phosphorylation of S6K at Thr389 is mediated by mTOR and most critical for function of S6K, this antibody appears best to assess expression and activity of S6K simultaneously [53, 60] . Blocking peptides specific for these antibodies were available from the cognate manufacturers. Staining intensity was classified as absent (−), weak (+), moderate (++) or strong (+++). With the exception of Ki-67, in all samples a widespread staining of the cystic epithelia was observed. Therefore, the score is based almost exclusively on the staining intensity [37] . n.d. = not done. epithelium whereas in four samples no Ki-67 expression was detectable at all. In healthy controls, Ki-67 positive cells were seen occasionally.
Activation of the AKT-mTOR signalling cascade
Serial sections of ARPKD kidneys were incubated with antibodies specific for phosphorylated mTOR, activated AKT as an important upstream regulator of mTOR and S6K as a functional readout parameter for mTOR activation. In all specimens, antibodies specific for these three proteins stained virtually all cystic epithelia, although staining intensity varied between samples ( Figure 3B ). Semiquantitative evaluation revealed a strong staining (i.e. ≥ ++) for AKT, mTOR and S6K in 13, 10 and 13 out of 14 kidney specimens, respectively (Table 4) . In healthy controls positive staining with the same panel of antibodies was seen occasionally.
Discussion
ARPKD is a rare but severe hereditary disease associated with a high perinatal mortality and rapidly progressive chronic renal failure often resulting in end-stage renal disease during childhood. In this study, we could clearly demonstrate activation of the AKT/mTOR signalling in nephrectomy specimens of children with clinically and genetically proven ARPKD. Thus, for these patients inhibition of mTOR might be an option to attenuate proliferation and growth of cystic epithelium, thereby slowing down progression of renal failure. All patients enrolled in this study displayed the 'classical' clinical course of ARPKD, suffered from end-stage renal disease at early childhood and presented with mild to severe (< −2 SD) growth retardation at the time of nephrectomy. Patient HH10 had already undergone nephrectomy 11 days after birth and at that time signs for hepatic involvement were absent. However, the remnant kidney had to be removed due to extensive growth at the age of about 6 months. At 1 year of age, she revealed signs of beginning portal hypertension and hepatic fibrosis at ultrasonographic examination.
Genetic findings
For ARPKD and PKHD1, it is widely accepted that genotype-phenotype correlations can be drawn for the type of mutation rather than for the site of individual mutations [36, 38, 39] . All patients carrying two truncating mutations display a severe phenotype with peri-or neonatal demise while patients surviving the neonatal period bear at least one missense mutation. Although the converse did not apply and some missense changes are obviously as devastating as truncating mutations, missense changes are more frequently observed among patients with a rather moderate clinical course, whereas chain-terminating mutations are more commonly associated with a severe phenotype. No significant clinical differences could be observed between patients with two missense mutations and those patients harbouring a truncating mutation in trans; thus, the milder mutation obviously defines the clinical phenotype. In accordance with these data, the vast majority of our patients harbour PKHD1 missense mutations.
One may speculate about the reasons that in some of our patients only one heterozygous or even no PKHD1 mutation was identified. Given the above arguments in favour of ARPKD in the two patients without a mutation, misdiagnosis might be rather unlikely. Among these patients, locus heterogeneity for ARPKD has to be kept in mind. Especially in those patients who bear a clearly pathogenic heterozygous PKHD1 mutation, failure to detect mutations may be explainable by several reasons. First, missing mutations may reside in regulatory elements and/or introns, distant from the splice donor and acceptor sites, that have not been screened so far, but which may lead to aberrant splicing. Alternatively, other mutational mechanisms, e.g. epigenetic alterations or gross genomic rearrangements (deletions, duplications, etc.) cannot be excluded [41] . Although deletion of the whole gene is unlikely, as in most cases heterozygosity for various non-pathogenic single nucleotide changes scattered throughout the PKHD1 gene was observed, deletions of one or a few exons or other genomic rearrangements cannot be ruled out in our DHPLC screened patients. Of course, limited sensitivity of the DHLPC approach has to be discussed as well.
Immunohistochemistry
All samples showed the typical histological pattern of ARPKD, e.g. radially orientated dilated collecting ducts and (few) interspersed normal glomeruli (Figure 1 ). Immunohistochemical investigation with the FPC specific mAb 18 demonstrated intense cytoplasmatic and membranous staining in cystic epithelia of all samples, whereas with mAb 5a only very faint stainings were obtained (Figure 2 ). In contrast, probing healthy kidney with mAbs 18 and 5a revealed quite coherent (and to the tubules, restricted) signals. Both antibodies recognize epitopes located either at the very distal part of the N-terminal domain (aa 143-238; mAb 18) or the C-terminal cytoplasmatic tail (mAb 5a) and none of the mutations identified is directly related to these parts of FPC. However, evidence was obtained, that binding of mAb 5a depends on proper post-translational modification (i.e. phosphorylation) of the intracytoplasmatic domain, and it might well be, that this is impaired due to even distant aberrations within the structure of FPC. The situation might be even more complicated as different FPC isoforms secondary to alternative splicing are likely to exist and to be recognized by these antibodies. However, immunohistochemistry is not suited to address this issue properly. Similar results with respect to expression and localization of FPC in ARPKD kidneys were also obtained by others, although antibodies recognizing different FPC-specific epitopes were used throughout these studies [3, 42, 43] . Interestingly, within our set of samples, ARPKD kidneys showed much stronger staining than the healthy control. While absence of FPC expression as a consequence of two truncating alleles has been associated with a severe phenotype and peri-or neonatal demise, it might be not the absence of FPC but rather the aberrant and uncontrolled expression of this multidomain protein that postnatally drives the proliferation of the tubular cells [2] .
Point mutations inside the coding sequence may modulate the physicochemical properties of the protein including (i) posttranslational modifications (change of phosphorylation and/or glycosylation sites), (ii) the stability of the mature protein with respect to proteolytic cleavage and (iii) the interaction with other molecules. In fact, the modular structure of FPC, i.e. the large, extracellular part with its numerous glycosylation sites and domains typically found in receptor proteins together with a rather short C-terminal cytoplasmatic domain harbouring potential phosphorylation sites classify FPC as a putative transducer of extracellular information [7] [8] [9] [10] [42] [43] [44] [45] [46] . However, the physiological ligand for FPC is still not known. The same holds true for the sequence of events leading from a mutated FPC to the proliferative phenotype of cystic epithelium [19] . Most likely, unregulated proliferation results from aberrant expression and activation of receptor tyrosine kinases (RTK) alone or in combination with the disturbed intracellular Ca 2+ homeostasis, which might be a direct consequence of an even slightly impaired protein network. In fact, most if not all proteins associated with cystic kidney disease are located either at the basal body or at the axoneme and evidence for a physical interaction between PC-1, PC-2 and FPC was obtained recently [18, 19, 21, 47] . Thus, the primary cilium might have to be envisaged as an extremely sensitive cell organelle and subtle changes in one of these proteins are likely to be of tremendous impact for the function of this cellular subunit. In a healthy kidney, virtually every epithelial cell lining the tubules bears a cilium, protruding into the lumen as a kind of chemo-and/or mechanosensor.
The localization of only one primary cilium at the luminal cell surface defines the spatial orientation of the cell relative to their neighbours and it is this spatial orientation (or polarization) that is also lost in ARPKD and other cystic kidney diseases. On a molecular level, the missing polarization translates into the aberrant expression of transporter proteins and ion-channels [48] . Among the consequence of an impaired ion-and salt-trafficking is an impairment of intracellular calcium homeostasis [12, 49, 50] . Furthermore, the polarization defect is associated with the aberrant expression and continuous (over-) activation of growth factor receptors, mostly belonging to the family of RTKs [48, 51] .
Both an impaired intracellular calcium homeostasis and the continuous stimulation of RTK result in a proliferative phenotype where the physiological mechanisms controlling cell proliferation and growth are no longer operable. Regardless of the individual triggering event, numerous pathways related to cell growth and proliferation impinge on mTOR and aberrant activation of mTOR were shown in several malignant and benign proliferation disorders including ADPKD [13, [25] [26] [27] [28] 32, 33, 52, 53] . Several pre-clinical and clinical trials have shown that rapamycin, a selective inhibitor of mTOR, is able to attenuate cell growth and proliferation, thereby slowing progression of proliferative disease [13, [25] [26] [27] [28] 32] .
Since up to date virtually nothing is known about the involvement of the mTOR pathway in ARPKD, we performed an immunohistochemical investigation with archival tissues. In addition, a Ki-67 specific antibody was used to assess the proliferative activity. Although on the one hand immunohistochemistry is per se not suited to clarify biological relevant function of the targeted molecule, a sufficient number of freshly frozen tissue samples from ARPKD patients was hardly available to address this issue. To solve this dilemma and to get at least an impression on the pathophysiological relevance of our findings, we used serial sections of archival tissue together with antibodies selectively recognizing the active isoforms of the respective kinases. To elucidate the mTOR pathway, we decided not only to investigate the status of mTOR and its down-stream target S6K but also to include AKT, which is activated by phospholipid binding. The latter can be envisaged as a second messenger generated through activation of PI3K by numerous cell surface receptors including RTKs [28, [30] [31] [32] 34, 53, 54] . We were able to show that the activated (phosphorylated) isoforms of AKT, mTOR and S6K were strongly expressed in virtually all samples investigated and, perhaps more important, almost co-localize in cystic epithelium (Figure 3) . Interestingly, Ki-67 positive cells were seen at much lower frequency, suggesting that growth, i.e. the increase in the cell size, is the primary event. This is grossly in accordance with a previous report [55] . In line with this, also in healthy kidneys of children, which are supposed to grow, Ki-67 was detected at an even lower frequency and only occasionally whereas activated AKT, mTOR and S6K were moderately expressed. Taken together, our results strongly suggest that mTOR-signalling plays an active role in the progression of ARPKD, i.e. in growing of the cystic epithelium. If this holds true, inhibition of mTOR by virtue of rapamycin would be an option to attenuate progression of the disease. This is of particular interest, as therapeutic interventions directed to targeted inhibition of cell proliferation by means of inhibitors specific for either RTKs or the cAMP-mediated pathways so far were rather disappointing in view of renal and hepatic outcome [12, 35, 56, 57] .
